Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Rev1 Ventures

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 223
Average round size
The average size of a deal this fund participated in
Portfolio companies 148
Rounds per year 13.12
Lead investments 28
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 18
Key employees 10
Stages of investment
Early Stage Venture

Areas of investment

  • Software
  • Health Care
  • Information Technology
  • Biotechnology
  • SaaS

Rev1 Ventures is the famous VC, which was founded in 2005. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Columbus.

Opposing the other organizations, this Rev1 Ventures works on 23 percentage points less the average amount of lead investments. When the investment is from Rev1 Ventures the average startup value is 5-10 millions dollars. The fund is generally included in 7-12 deals every year. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. The usual things for fund are deals in the range of 1 - 5 millions dollars. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.

The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Rev1 Ventures, startups are often financed by NCT Ventures, Charter Life Sciences, 10Xelerator. The meaningful sponsors for the fund in investment in the same round are NCT Ventures, JumpStart Inc., Tamarind Hill. In the next rounds fund is usually obtained by JumpStart Inc., Tamarind Hill, PointGuard Ventures.

Besides them, we counted 10 critical employees of this fund in our database.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Information Technology, Enterprise Software. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Unific, Seen Digital Media, Inc., ClearSaleing

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

STAQ Pharma

02 Mar 2022 Denver, Colorado, United States

Artificial Intelligence
Automation/Workflow Software
Big Data
Business Intelligence
Business/Productivity Software
Internet of Things
Machine Learning
Natural Language Processing
Semantic Search
Supply Chain Management
$4M27 Jan 2022 Indianapolis, Indiana, United States


Artificial Intelligence
Impact Investing
$2M18 Jan 2022 San Francisco, California, United States

Healthy Roster

Health Care
$2M22 Oct 2021 Ohio, United States


Artificial Intelligence
Business Intelligence
Cyber Security
Enterprise Software
Risk Management
$60M13 Oct 2021 Columbus, Ohio, United States


Health Care
$1M31 Aug 2021 Columbus, Ohio, United States

Driver Technologies

Mobile Apps
Social Media
$8M01 Jun 2021 New York, New York, United States

Eikonoklastes Therapeutics

Life Science
$3M06 May 2021 Cincinnati, Ohio, United States


Artificial Intelligence
Business Intelligence
Cyber Security
Enterprise Software
Risk Management
$12M14 Dec 2020 Columbus, Ohio, United States
Eikonoklastes Closes Series A Funding

– Eikonoklastes Therapeutics from Cincinnati, Ohio develops immunotherapies to treat a broad range of cancers beginning with Triple Negative Breast Cancer (TNBC), a lethal form of breast cancer that comprises 15% of all breast cancers.
– The company raised an undisclosed amount in Series A funding.
– The round was led by CincyTech with participation from New York-based Elk Capital Ventures, Jobs Ohio, Rev1, and other undisclosed investors.
– The new investment will be used to conduct Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Rev1 Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: